The biotech world is a prime target for risk-tolerant investors seeking out companies with the potential for dramatic gains. Firms in this space often either make it big—spiking upon news of a ...
The last time I spoke about Absci Corporation (ABSI), it was in a Seeking Alpha article entitled "Absci: AI-Driven Platform Could Establish Best-In-Class TL1A Drug Targeting Profile." The hope here ...
Advanced Micro Devices Inc. today announced that it has invested $20 million in Absci Corp., a company using artificial intelligence to develop new medicines. AMD will also partner with the company to ...
Fifth-generation AMD EPYC processors and RDMA cluster networking power OCI’s bare metal instances. They provide Absci with the low-latency networking and throughput required for large-scale model ...
Needham analyst has initiated coverage on Absci Corporation (NASDAQ:ABSI), a drug and target discovery company that harnesses deep learning AI and synthetic biology to expand proteins’ therapeutic ...
KOL seminar scheduled for December 11 to discuss new human ex vivo data, clinical trial design, and market opportunity in AGA VANCOUVER, Wash. and NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Absci ...
Absci CEO Sean McClain Absci says it is about a year away from its lead AI-designed therapeutic entering the clinic—one of several pipeline candidates whose development the company says it will be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results